• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在分布式网络和多地点药物流行病学研究中向特定目标人群标准化。

Standardizing to specific target populations in distributed networks and multisite pharmacoepidemiologic studies.

出版信息

Am J Epidemiol. 2024 Jul 8;193(7):1031-1039. doi: 10.1093/aje/kwae015.

DOI:10.1093/aje/kwae015
PMID:38412261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11520739/
Abstract

Distributed network studies and multisite studies assess drug safety and effectiveness in diverse populations by pooling information. Targeting groups of clinical or policy interest (including specific sites or site combinations) and applying weights based on effect measure modifiers (EMMs) prior to pooling estimates within multisite studies may increase interpretability and improve precision. We simulated a 4-site study, standardized each site using inverse odds weights (IOWs) to resemble the 3 smallest sites or the smallest site, estimated IOW-weighted risk differences (RDs), and combined estimates with inverse variance weights (IVWs). We also created an artificial distributed network in the Clinical Practice Research Datalink (CPRD) Aurum consisting of 1 site for each geographic region. We compared metformin and sulfonylurea initiators with respect to mortality, targeting the smallest region. In the simulation, IOWs reduced differences between estimates and increased precision when targeting the 3 smallest sites or the smallest site. In the CPRD Aurum study, the IOW + IVW estimate was also more precise (smallest region: RD = 5.41% [95% CI, 1.03-9.79]; IOW + IVW estimate: RD = 3.25% [95% CI, 3.07-3.43]). When performing pharmacoepidemiologic research in distributed networks or multisite studies in the presence of EMMs, designation of target populations has the potential to improve estimate precision and interpretability. This article is part of a Special Collection on Pharmacoepidemiology.

摘要

分布式网络研究和多地点研究通过汇总信息来评估不同人群中的药物安全性和有效性。在多地点研究中,针对具有临床或政策意义的目标群体(包括特定地点或地点组合),并在汇总估计值之前基于效应量修正因子(EMM)应用权重,可能会提高可解释性并提高精度。我们模拟了一个 4 个地点的研究,使用逆概率权重(IOW)对每个地点进行标准化,以类似于 3 个最小的地点或最小的地点,估计 IOW 加权风险差异(RD),并使用倒数方差权重(IVW)合并估计值。我们还在临床实践研究数据链接(CPRD)Aurum 中创建了一个人工分布式网络,每个地理区域都有一个地点。我们针对死亡率比较了二甲双胍和磺酰脲类药物的启动者,目标是最小的地区。在模拟中,当针对 3 个最小的地点或最小的地点时,IOW 减少了估计值之间的差异并提高了精度。在 CPRD Aurum 研究中,IOW+IVW 估计值也更加精确(最小地区:RD = 5.41%[95%CI,1.03-9.79];IOW+IVW 估计值:RD = 3.25%[95%CI,3.07-3.43])。当在存在 EMM 的分布式网络或多地点研究中进行药物流行病学研究时,目标人群的指定有可能提高估计值的精度和可解释性。本文是药物流行病学特刊的一部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/3bf0a2c4288c/kwae015f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/8564ee15d593/kwae015f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/9047b72bb518/kwae015f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/72b8311440ff/kwae015f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/37904d9396ea/kwae015f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/f1524380141c/kwae015f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/3bf0a2c4288c/kwae015f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/8564ee15d593/kwae015f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/9047b72bb518/kwae015f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/72b8311440ff/kwae015f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/37904d9396ea/kwae015f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/f1524380141c/kwae015f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6438/11520739/3bf0a2c4288c/kwae015f6.jpg

相似文献

1
Standardizing to specific target populations in distributed networks and multisite pharmacoepidemiologic studies.在分布式网络和多地点药物流行病学研究中向特定目标人群标准化。
Am J Epidemiol. 2024 Jul 8;193(7):1031-1039. doi: 10.1093/aje/kwae015.
2
Variable selection when estimating effects in external target populations.在外部目标人群中估计效应时的变量选择。
Am J Epidemiol. 2024 Aug 5;193(8):1176-1181. doi: 10.1093/aje/kwae048.
3
Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.二甲双胍不会影响癌症风险:一项在英国临床实践研究数据链中进行的类似于意向治疗试验的队列研究分析。
Diabetes Care. 2014 Sep;37(9):2522-32. doi: 10.2337/dc14-0584. Epub 2014 Jun 4.
4
Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.磺脲类药物与二甲双胍单药治疗对心力衰竭风险的比较安全性:一项队列研究。
J Am Heart Assoc. 2017 Apr 19;6(4):e005379. doi: 10.1161/JAHA.116.005379.
5
Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.基于英国初级保健数据与住院和死亡率记录关联的回顾性队列研究:与二线抗糖尿病治疗相关的主要心血管事件的比较风险。
Diabetes Obes Metab. 2016 Sep;18(9):916-24. doi: 10.1111/dom.12692. Epub 2016 Jun 30.
6
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.英国前瞻性糖尿病研究24:一项为期6年的随机对照试验,比较磺脲类药物、胰岛素和二甲双胍疗法对新诊断的、饮食疗法无法控制的2型糖尿病患者的疗效。英国前瞻性糖尿病研究小组。
Ann Intern Med. 1998 Feb 1;128(3):165-75. doi: 10.7326/0003-4819-128-3-199802010-00001.
7
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.与磺脲类单药治疗相比,使用二甲双胍可降低2型糖尿病患者的死亡率。
Diabetes Care. 2002 Dec;25(12):2244-8. doi: 10.2337/diacare.25.12.2244.
8
Diabetes, use of metformin, and the risk of meningioma.糖尿病、二甲双胍的使用与脑膜瘤风险
PLoS One. 2017 Jul 14;12(7):e0181089. doi: 10.1371/journal.pone.0181089. eCollection 2017.
9
More realistic power estimation for new user, active comparator studies: an empirical example.针对新用户的更现实的功效估计、活性对照研究:一个实证例子。
Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):462-6. doi: 10.1002/pds.3872. Epub 2015 Sep 11.
10
Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes.MASTERMIND研究的队列概况:利用临床实践研究数据链(CPRD)调查2型糖尿病患者治疗反应的分层情况
BMJ Open. 2017 Oct 12;7(10):e017989. doi: 10.1136/bmjopen-2017-017989.

引用本文的文献

1
The AMerican PREGNANcy Mother-Child CohorT: description and prevalence of baseline outcomes and medication dispensing.美国母婴队列研究:基线结局及药物配给情况的描述与患病率
Front Pharmacol. 2025 Aug 5;16:1608403. doi: 10.3389/fphar.2025.1608403. eCollection 2025.
2
When, why and how are estimated effects transported between populations? A scoping review of studies applying transportability methods.估计效应在不同人群之间是何时、为何以及如何传递的?一项应用可传递性方法的研究的范围综述。
Eur J Epidemiol. 2025 Apr 18. doi: 10.1007/s10654-025-01217-w.

本文引用的文献

1
External validity in distributed data networks.分布式数据网络中的外部有效性。
Pharmacoepidemiol Drug Saf. 2023 Dec;32(12):1360-1367. doi: 10.1002/pds.5666. Epub 2023 Jul 18.
2
Systematically missing data in causally interpretable meta-analysis.因果可解释的荟萃分析中系统性缺失的数据。
Biostatistics. 2024 Apr 15;25(2):289-305. doi: 10.1093/biostatistics/kxad006.
3
How Choice of Effect Measure Influences Minimally Sufficient Adjustment Sets for External Validity.效应量的选择如何影响外部有效性的最小充分调整集。
Am J Epidemiol. 2023 Jul 7;192(7):1148-1154. doi: 10.1093/aje/kwad041.
4
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.磺脲类药物与二甲双胍在 2 型糖尿病患者中心律失常风险的比较:一项基于人群的队列研究。
Diabetes Obes Metab. 2023 Jun;25(6):1523-1533. doi: 10.1111/dom.15000. Epub 2023 Feb 16.
5
Meta-analysis with sample-standardization in multi-site studies.多中心研究中采用样本标准化的Meta分析。
Pharmacoepidemiol Drug Saf. 2023 Jan;32(1):56-59. doi: 10.1002/pds.5527. Epub 2022 Sep 2.
6
Generative adversarial networks and synthetic patient data: current challenges and future perspectives.生成对抗网络与合成患者数据:当前挑战与未来展望
Future Healthc J. 2022 Jul;9(2):190-193. doi: 10.7861/fhj.2022-0013.
7
Target validity: Bringing treatment of external validity in line with internal validity.目标效度:使外部效度的处理与内部效度保持一致。
Curr Epidemiol Rep. 2020 Sep;7(3):117-124. doi: 10.1007/s40471-020-00239-0. Epub 2020 Jun 30.
8
Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population.从随机试验到目标人群推广因果推论的研究设计。
Am J Epidemiol. 2021 Aug 1;190(8):1632-1642. doi: 10.1093/aje/kwaa270.
9
Directed Acyclic Graphs, Effect Measure Modification, and Generalizability.有向无环图、效应修正和可推广性。
Am J Epidemiol. 2021 Feb 1;190(2):322-327. doi: 10.1093/aje/kwaa185.
10
Extending inferences from a randomized trial to a new target population.将随机试验的推断扩展到新的目标人群。
Stat Med. 2020 Jun 30;39(14):1999-2014. doi: 10.1002/sim.8426. Epub 2020 Apr 6.